Your browser doesn't support javascript.
Epidemiological comparison of the first and second waves of the COVID-19 pandemic in Nigeria, February 2020-April 2021.
Akande, Oluwatosin Wuraola; Elimian, Kelly Osezele; Igumbor, Ehimario; Dunkwu, Lauryn; Kaduru, Chijioke; Olopha, Olubunmi Omowunmi; Ohanu, Dabri Olohije; Nwozor, Lilian; Agogo, Emmanuel; Aruna, Olusola; Balogun, Muhammad Shakir; Aderinola, Olaolu; Ahumibe, Anthony; Arinze, Chinedu; Badaru, Sikiru Olanrewaju; Nwachukwu, William; Dada, Augustine Olajide; Erameh, Cyril; Hamza, Khadeejah; Mohammed, Tarik Benjamin; Ndodo, Nnaemeka; Obiekea, Celestina; Ofoegbunam, Chinenye; Ogunbode, Oladipo; Ohonsi, Cornelius; Tobin, Ekaete Alice; Yashe, Rimamdeyati; Adekaiyaoja, Afolabi; Asuzu, Michael C; Audu, Rosemary Ajuma; Bello, Muhammad Bashir; Bello, Shaibu Oricha; Deeni, Yusuf Yahaya; Disu, Yahya; Joseph, Gbenga; Ezeokafor, Chidiebere; Habib, Zaiyad Garba; Ibeh, Christian; Ike, Ifeanyi Franklin; Iwara, Emem; Luka-Lawal, Rejoice Kudirat; Namara, Geoffrey; Okwor, Tochi; Olajide, Lois; Ilesanmi, Oluwafunke Olufemi; Omonigho, Solomon; Oyiri, Ferdinand; Takpa, Koubagnine; Ugbogulu, Nkem Usha; Ibekwe, Priscilla.
  • Akande OW; Prevention Programmes & Knowledge Management, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria akande.wuraola@gmail.com.
  • Elimian KO; Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.
  • Igumbor E; Prevention Programmes & Knowledge Management, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.
  • Dunkwu L; Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.
  • Kaduru C; Department of Global Public Health, Karolinska Institute, Stockholm, Sweden.
  • Olopha OO; Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.
  • Ohanu DO; Office of the Director General, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.
  • Nwozor L; School of Public Health, University of the Western Cape, Bellville, South Africa.
  • Agogo E; Tony Blair Institute for Global Change, Abuja, Federal Capital Territory, Nigeria.
  • Aruna O; Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.
  • Balogun MS; IQVIA, Abuja, Nigeria.
  • Aderinola O; Prevention Programmes & Knowledge Management, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.
  • Ahumibe A; Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.
  • Arinze C; Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.
  • Badaru SO; Office of the Director General, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.
  • Nwachukwu W; Prevention Programmes & Knowledge Management, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.
  • Dada AO; Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.
  • Erameh C; Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.
  • Hamza K; Resolve to Save Lives, Abuja, Federal Capital Territory, Nigeria.
  • Mohammed TB; International Health Regulations (IHR) Strengthening Project, Global Operations, UK Health Security Agency, London, UK.
  • Ndodo N; African Field Epidemiology Network, Abuja, Federal Capital Territory, Nigeria.
  • Obiekea C; Health Emergency Preparedness and Response, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.
  • Ofoegbunam C; Public Health Laboratory Services, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.
  • Ogunbode O; Surveillance and Epidemiology, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.
  • Ohonsi C; Prevention Programmes & Knowledge Management, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.
  • Tobin EA; Surveillance and Epidemiology, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.
  • Yashe R; African Field Epidemiology Network, Abuja, Federal Capital Territory, Nigeria.
  • Adekaiyaoja A; Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria.
  • Asuzu MC; Department of Community Medicine, Ahmadu Bello University, Zaria, Nigeria.
  • Audu RA; Office of the Director General, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.
  • Bello MB; Public Health Laboratory Services, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.
  • Bello SO; Public Health Laboratory Services, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.
  • Deeni YY; Surveillance and Epidemiology, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.
  • Disu Y; Prevention Programmes & Knowledge Management, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.
  • Joseph G; Prevention Programmes & Knowledge Management, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.
  • Ezeokafor C; Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.
  • Habib ZG; Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria.
  • Ibeh C; Surveillance and Epidemiology, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.
  • Ike IF; Tony Blair Institute for Global Change, Abuja, Federal Capital Territory, Nigeria.
  • Iwara E; Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.
  • Luka-Lawal RK; Department of Community Medicine, University College Hospital, Ibadan, Oyo State, Nigeria.
  • Namara G; Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.
  • Okwor T; Department of Microbiology, Nigerian Institute of Medical Research, Yaba, Lagos State, Nigeria.
  • Olajide L; Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.
  • Ilesanmi OO; Center for Advanced Medical Research and Training, Usmanu Danfodiyo University, Sokoto, Sokoto State, Nigeria.
  • Omonigho S; Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.
  • Oyiri F; Department of Pharmacology & Therapeutics, College of Health Sciences, Usmanu Danfodiyo University, Sokoto, Sokoto State, Nigeria.
  • Takpa K; Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.
  • Ugbogulu NU; Department of Microbiology & Biotechnology, Federal University Dutse, Dutse, Jigawa State, Nigeria.
  • Ibekwe P; Centre for Environmental and Public Health Research and Development, Kano, Kano State, Nigeria.
BMJ Glob Health ; 6(11)2021 11.
Article in English | MEDLINE | ID: covidwho-1526499
ABSTRACT

BACKGROUND:

With reports of surges in COVID-19 case numbers across over 50 countries, country-level epidemiological analysis is required to inform context-appropriate response strategies for containment and mitigation of the outbreak. We aimed to compare the epidemiological features of the first and second waves of COVID-19 in Nigeria.

METHODS:

We conducted a retrospective analysis of the Surveillance Outbreak Response Management and Analysis System data of the first and second epidemiological waves, which were between 27 February and 24 October 2020, and 25 October 2020 to 3 April 2021, respectively. Descriptive statistical measures including frequencies and percentages, test positivity rate (TPR), cumulative incidence (CI) and case fatality rates (CFRs) were compared. A p value of <0.05 was considered statistically significant. All statistical analyses were carried out in STATA V.13.

RESULTS:

There were 802 143 tests recorded during the study period (362 550 and 439 593 in the first and second waves, respectively). Of these, 66 121 (18.2%) and 91 644 (20.8%) tested positive in the first and second waves, respectively. There was a 21.3% increase in the number of tests conducted in the second wave with TPR increasing by 14.3%. CI during the first and second waves were 30.3/100 000 and 42.0/100 000 respectively. During the second wave, confirmed COVID-19 cases increased among females and people 30 years old or younger and decreased among urban residents and individuals with travel history within 14 days of sample collection (p value <0.001). Most confirmed cases were asymptomatic at diagnosis during both waves 74.9% in the first wave; 79.7% in the second wave. CFR decreased during the second wave (0.7%) compared with the first wave (1.8%).

CONCLUSION:

Nigeria experienced a larger but less severe second wave of COVID-19. Continued implementation of public health and social measures is needed to mitigate the resurgence of another wave.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pandemics / COVID-19 Type of study: Observational study / Prognostic study Limits: Adult / Female / Humans Country/Region as subject: Africa Language: English Year: 2021 Document Type: Article Affiliation country: Bmjgh-2021-007076

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pandemics / COVID-19 Type of study: Observational study / Prognostic study Limits: Adult / Female / Humans Country/Region as subject: Africa Language: English Year: 2021 Document Type: Article Affiliation country: Bmjgh-2021-007076